Regina Soehnlein
Family · Minneapolis, MNNPI 1467664458
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 46 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 14.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $2,015 and has fallen 56.7% since, to $873 in 2025. Among family clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 46 payments — averaging $99.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$676
- Boston Scientific$444
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$437
- Amgen$248
- Gilead$247
- Otsuka America Pharmaceutical, Inc.$232
- plus $2K from 17 others
What the payments were for
- Food & beverage$4,587100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 6 | $676 |
| Boston Scientific | 5 | $444 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $437 |
| Amgen | 2 | $248 |
| Gilead | 2 | $247 |
| Otsuka America Pharmaceutical, Inc. | 2 | $232 |
| Viiv Healthcare Company | 2 | $228 |
| Impel Pharmaceuticals Inc. | 2 | $219 |
| Sanofi-aventis U.S. LLC | 2 | $189 |
| Tris Pharma Inc | 3 | $183 |
| Coloplast | 3 | $178 |
| Grifols USA, LLC | 1 | $136 |
| Johnson & Johnson | 1 | $135 |
| GSK | 1 | $120 |
| Novo Nordisk | 1 | $118 |
| Bayer | 1 | $115 |
| Genentech USA, Inc. | 1 | $111 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $110 |
| Axsome Therapeutics, Inc. | 1 | $109 |
| AbbVie | 1 | $107 |
| Corium, LLC | 1 | $93 |
| Idorsia Pharmaceuticals US Inc | 2 | $78 |
| AstraZeneca | 1 | $76 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,587 in reported general payments places this provider in the 95th percentile of 1,121 family providers in Minnesota.
Other family in Minneapolis
- Julia GourdeMinneapolis$65K
- Robin DontaMinneapolis$60K
- Kristin WeberMinneapolis$35K
- Kathleen FredellMinneapolis$28K
- Diana CzelMinneapolis$24K
- Elisa RiveroMinneapolis$16K
- Marcia SimmondsMinneapolis$10K
- Rachel StenachMinneapolis$7K
- Kathryn TietzMinneapolis$3K
- Ashley EnglishMinneapolis$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.